Figures & data
Table 1 Baseline demographics and patient disposition in subgroups of randomized patients stratified by age from a 12-week randomized, placebo-controlled study of AOM 400 in adults experiencing an acute psychotic episode
Figure 1 Change from baseline in PSP total score in subgroups stratified by age in Study 291.
Abbreviations: ANCOVA, analysis of covariance; AOM 400, aripiprazole once-monthly 400 mg; LSM, least square means; MMRM, mixed model repeated measures; OC, observed cases; PSP, Personal and Social Performance.
Table 2 Mean change from baseline to last visit in PSP total score and domain scores: 52-week, open-label extension study of AOM 400 as maintenance treatment
Figure 2 Change from baseline in PSP total score (A) and individual domain scores (B) from Study 248.
Abbreviations: AOM 400, aripiprazole once-monthly 400 mg; OC, observed cases; PSP, Personal and Social Performance; SD, standard deviation.
Figure 3 Categorical changes in PSP total scores from baseline (prior to OA stabilization) through (A) last visit and (B) at 52 weeks (observed cases) of open-label treatment in Study 248.
Abbreviations: OC, observed cases; PSP, Personal and Social Performance.
Table 3 Adverse events during acute and maintenance treatment in Studies 291 and 248